Organon Q3 revenues $1.54B (-4% YoY); raises FY adjusted EBITDA margin guidance

Organon & Co.

2022-Q3 EPS reported $3.17 revenue$4,689,000,000

Q3 revenue $1,537M, down 4% YoY as-reported but up 3% ex-FX.
GAAP diluted EPS $0.89, non-GAAP adjusted diluted EPS $1.32.
Women's Health revenue grew 19% (23% ex-FX) on Nexplanon demand.
Full year 2022 revenue guidance narrowed to $6.1-$6.2B; adjusted EBITDA margin raised to 33.5%-34.5%.
Board declares quarterly dividend of $0.28 per share.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Organon & Co. reported the third quarter ended September 30, 2022 results: revenue $1,537 million, net income 227, EPS $0.89.

Period: the third quarter ended September 30, 2022
Revenue: $1,537 million
Net income: 227
EPS: $0.89
Result: reported results

Exact text from the filing

Halchak (614) 314-8094 Kate Vossen (732) 675-8448 (201) 275-2711 Organon rep orts results for the third quarter ended September 30, 2022 · Third quarter 2022 revenues of $1,537 million · Third quarter diluted earnings per share from continuing operations of $0.89 and non-GAAP adjusted diluted earnings per share from continuing operations of $1.32 · Both

View on SEC.gov

Browse all earnings releases →

Organon & Co. filing history →

Source: SEC EDGAR

accession 0001104659-22-114226

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.